| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = -$1,800 ) |
| | 2022 | 2017 | PAPGENE, INC. | 1812 ASHLAND AVE STE 640 | BALTIMORE | MD | 21205-1546 | BALTIMORE CITY | USA | R44CA203350 | Genetic Cytology for Ovarian and Endometrial Cancer Screening | 001 | 3 | NIH | 6/29/2022 | -$1,800 |
|
| Issue Date FY: 2020 ( Subtotal = -$83,803 ) |
| | 2020 | 2017 | PAPGENE, INC. | 1812 ASHLAND AVE STE 640 | BALTIMORE | MD | 21205-1546 | BALTIMORE CITY | USA | R44CA203350 | Genetic Cytology for Ovarian and Endometrial Cancer Screening | 000 | 3 | NIH | 7/15/2020 | -$83,803 |
|
| Issue Date FY: 2017 ( Subtotal = $994,554 ) |
| | 2017 | 2017 | PAPGENE, INC. | 810 WYMAN PARK DR | BALTIMORE | MD | 21211-2840 | BALTIMORE CITY | USA | R44CA203350 | Genetic Cytology for Ovarian and Endometrial Cancer Screening | 000 | 3 | NIH | 8/15/2017 | $994,554 |
|
| Issue Date FY: 2016 ( Subtotal = $1,286,663 ) |
| | 2016 | 2016 | PAPGENE, INC. | 810 WYMAN PARK DR | BALTIMORE | MD | 21211 | BALTIMORE CITY | USA | R44CA203350 | Genetic Cytology for Ovarian and Endometrial Cancer Screening | 001 | 1 | NIH | 8/26/2016 | $0 |
| | 2016 | 2016 | PAPGENE, INC | 810 WYMAN PARK DR | BALTIMORE | MD | 21211 | BALTIMORE CITY | USA | R44CA203350 | Genetic Cytology for Ovarian and Endometrial Cancer Screening | 000 | 1 | NIH | 1/20/2016 | $296,784 |
| | 2016 | 2016 | PAPGENE, INC | 810 WYMAN PARK DR | BALTIMORE | MD | 21211 | BALTIMORE CITY | USA | R44CA203350 | Genetic Cytology for Ovarian and Endometrial Cancer Screening | 002 | 2 | NIH | 8/31/2016 | $989,879 |
|
|
